Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2090-2098

  Koppejan, H ^a   Trouw, L A ^a   Sokolove, J ^b   Lahey, L J ^b   Huizinga, T J W ^a   Smolik, I A ^c   Robinson, D B ^c   El Gabalawy, H S ^c   Toes, R E M ^a   Hitchon, C A ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICARBAMYLATED PROTEIN ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CAUCASIAN; CLINICAL EVALUATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST-DEGREE RELATIVE; HIGH RISK POPULATION; HUMAN; INDIGENOUS PEOPLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NORTH AMERICAN; ODDS RATIO; PRIORITY JOURNAL; RANK SUM TEST; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING;

EID: 84983548276     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39664     Document Type: Article

References (36)

1. Ferucci ED, Schumacher MC, Lanier AP, Murtaugh MA, Edwards S, Helzer LJ, et al. Arthritis prevalence and associations in American Indian and Alaska Native people. Arthritis Rheum 2008;59:1128–36.
2. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999;28:368–91.
3. Words first: an evolving terminology relating to Aboriginal peoples in Canada. Government of Canada, Communications Branch, Indian and Northern Affairs; 2002. URL: http://publications.gc.ca/collections/Collection/R2-236-2002E.pdf.
4. Peschken CA, Hitchon CA, Robinson DB, Smolik I, Barnabe CR, Prematilake S, et al. Rheumatoid arthritis in a North American native population: longitudinal followup and comparison with a white population. J Rheumatol 2010;37:1589–95.
5. El-Gabalawy HS, Robinson DB, Hart D, Elias B, Markland J, Peschken CA, et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol 2009;36:1130–5.
6. Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, et al. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 2010;37:1105–12.
7. Peschken CA, Robinson DB, Hitchon CA, Smolik I, Hart D, Bernstein CN, et al. Pregnancy and the risk of rheumatoid arthritis in a highly predisposed North American Native population. J Rheumatol 2012;39:2253–60.
8. Krol A, Garred P, Heegaard NH, Christensen AF, Hetland ML, Stengaard-Pedersen K, et al. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis. Scand J Rheumatol 2015;44:8–12.
9. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427–30.
10. Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, et al. Marked differences in fine specificity and isotype usage of the anti–citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000–8.
11. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014;73:780–3.
12. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Jol-van der Zijde CM, et al. Avidity maturation of anti–citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012;64:1323–8.
13. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741–9.
14. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380–6.
15. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PloS One 2012;7:e35296.
16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
17. Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al, and the CATCH Investigators. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 2014;41:2361–9.
18. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002–8.
19. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085–9.
20. Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann Rheum Dis 2015;74:579–86.
21. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108:17372–7.
22. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis 2014;73:1761–8.
23. Scinocca M, Bell DA, Racape M, Joseph R, Shaw G, McCormick JK, et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol 2014;41:270–9.
24. Odobasic D, Yang Y, Muljadi RC, O'Sullivan KM, Kao W, Smith M, et al. Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental arthritis. Arthritis Rheumatol 2014;66:907–17.
25. Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010;184:6882–90.
26. Muller PC, Anink J, Shi J, Levarht EW, Reinards TH, Otten MH, et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis 2013;72:2053–5.
27. Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, et al, the CATCH Investigators. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol 2013;40:1259–67.
28. Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK, et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol 2015;42:572–9.
29. Brink M, Verheul MK, Ronnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015;17:25.
30. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, et al. Anti–carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013;65:911–5.
31. Bernstein CN, El-Gabalawy H, Sargent M, Landers C, Rawsthorne P, Elias B, et al. Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts. Can J Gastroenterol 2011;25:269–73.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
33. El-Gabalawy HS, Robinson DB, Smolik I, Hart D, Elias B, Wong K, et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum 2012;64:1720–9.
34. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol 2002;29:2034–40.
35. Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, et al. Rheumatoid factor as a potentiator of anti–citrullinated protein antibody–mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 2014;66:813–21.
36. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2015;74:234–41.